Zealand Pharma A/S/ADR (ZLDPF)

Zealand Pharma A/S is a Danish biopharmaceutical company that discovers and develops drugs primarily in the metabolic and gastrointestinal disease space, with a particular focus on therapies that target glucagon and GLP-1 receptor pathways. The company does not manufacture drugs itself or run its own sales force; instead, it conducts clinical trials to demonstrate efficacy and safety, then partners with larger pharmaceutical companies to bring drugs to market. Its American Depositary Receipts trade on the NASDAQ under the ticker ZLDPF.

To understand Zealand is to understand biotech’s two-tier competition. On one tier, Zealand competes with large, integrated pharmaceutical companies like Novo Nordisk, Eli Lilly, and AstraZeneca that have their own research operations, massive pipelines, and global commercial machinery. Those companies can afford to pursue dozens of parallel drug programs, absorb failures, and spend billions to bring one drug to market. On another tier, Zealand competes with hundreds of other clinical-stage biotechs that are trying to prove a drug works before they run out of cash.

Zealand’s survival strategy has been to partner early and often. When a drug reaches a certain stage of development — sometimes after Phase II trials, sometimes after Phase III has begun — Zealand out-licenses it to a larger partner in exchange for upfront cash, regulatory milestones, and royalties on future sales. This is how the company funds operations: each upfront payment buys time to keep the research engine running and to move early-stage molecules forward. The biggest and best performing partnerships generate the most cash, extend the company’s runway the furthest, and attract investors who believe the underlying science is sound.

The company’s core scientific platform focuses on glucagon-like peptide 1, or GLP-1. This is a natural hormone that signals satiety (fullness), slows stomach emptying, and affects glucose metabolism — activating the GLP-1 receptor tells the body to eat less and improve blood-sugar control. Semaglutide (marketed by Novo Nordisk as Ozempic and Wegovy) and tirzepatide (marketed by Eli Lilly as Mounjaro and Zepbound) are GLP-1 agonists that have become blockbuster drugs. They are used to treat type 2 diabetes and, increasingly, obesity in people without diabetes. Zealand has pursued this same therapeutic area, betting that it can develop variants or delivery methods that offer advantages over what is already on the market.

This is where the competition becomes clear: Zealand is entering a space now dominated by enormous, profitable drugs made by megacap companies with massive research budgets and regulatory expertise. Novo Nordisk and Eli Lilly have invested decades in understanding GLP-1 biology and have access to the best scientists in the field. They can run massive clinical trials, employ armies of sales representatives, and offer doctors and patients a package of options (semaglutide in different formulations and doses, tirzepatide, combination products). Zealand, by contrast, is trying to innovate around the edges — perhaps with a different dosing schedule, a novel formulation (Zealand’s lead candidate has been an oral GLP-1, whereas the biggest competitors still rely on injectables), or efficacy claims that rival the established drugs.

The scientific bet is sound: if Zealand can demonstrate that its approach works as well or better than what exists, or solves a real problem the current drugs do not address, it has a commercial case. But the regulatory approval process is slow and expensive, running to hundreds of millions of dollars per drug. Competitors will be iterating and improving in that time, and by the time Zealand’s drug is approved, the landscape may have shifted — other companies may have solved the same problem, or the indications and patient populations may have changed. This is the gamble biotech investors accept when they back a company in a crowded therapeutic area.

Zealand’s partnerships have provided the capital cushion to fund this competition. The company has licensed drugs to partners including Roche, Boehringer Ingelheim, and others, diversifying its risk across multiple programs and partners rather than depending on a single drug. Each partnership also provides regulatory feedback and clinical expertise from the larger partner, raising the chances that the combined team can navigate approval successfully. The trade-off, of course, is that if any of these drugs becomes hugely successful, Zealand captures only a royalty stream, not the full commercial upside. But given the capital constraints of a small biotech, that is a rational choice: a smaller but certain stream of cash from a royalty is preferable to the risk of betting everything on an internal program that might fail.

The real competitive risk for Zealand is that the best scientists, the best early-stage molecules, and the most promising preclinical work inevitably flow toward the companies that can offer the most capital and the fastest path to patients. Large pharma can outbid smaller biotechs for talent and for acquisitions of promising early-stage companies. So Zealand must compete on the basis of a clear scientific thesis, a team of people who have won before and have conviction in the approach, and evidence of early efficacy that attracts the best partners. The company’s survival and ultimate success depend on being right about the science in a way that neither the biggest competitors nor the hundreds of smaller biotechs have figured out yet.

For investors, Zealand is a bet on the company’s science, its partnerships, and the competence of its leadership. The company carries substantial cash, which extends its runway, but also takes on the risk that none of its programs succeed — a not-uncommon outcome in biotech. A 10-K filing reveals the company’s cash position, its partnership agreements (which set milestones and payment schedules), and its pipeline stage by stage. Clinical trial results are the key driver of value; a positive Phase III trial or an approval from the FDA can dramatically shift the valuation. Conversely, a failed trial can lead to a sharp stock decline. This is why biotech investors are often scientists or sector specialists with deep conviction about the underlying biology — the financial volatility is too high for passive strategies.